Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HL151 vs Talion in Pruritus Cutaneus
NCT03317301Phase 3Completed
- Sponsor
- Hanlim Pharm
- Start
- May 2017
- Primary completion
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of bepotastine in pruritus (2 arms), sponsored by Hanlim Pharm. Primary endpoint: Changes in Visual Analogue Scale score at 2 weeks. Started May 2017; status: completed.
02
Drugs
bepotastine
03
Conditions
pruritus
Beyond the preview
Go deeper on NCT03317301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03317301.